MVRBF News and Press, Medivir B From 08/28/19

Medivir AB ( OTC:MVRBF ): Q2 GAAP EPS of -SEK0.51. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...

Medivir AB ( OTC:MVRBF ) initiated with Buy rating at H.C. Wainwright. More news on: Medivir AB (publ), Cassava Sciences, Inc., CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

STOCKHOLM , June 13, 2019 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) today announces the results of an analysis of data from the first six patients with advanced cancer in the liver treated with increasing MIV-818 doses. The primary objective of the study is t...

STOCKHOLM , June 4, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in Philadelphia , US. The presentation will take place at 11.30am local time on Wednesday, June 5, 2019 . Christina H...

STOCKHOLM , June 3, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in combination with pembrolizumab (Keytruda®) was presented at an oral session on June 2nd at the American Society of Clinical Oncology (A...

STOCKHOLM , May 27, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm . The presentation will take place at 9.15am on Tuesday, May 28, 2019 . Dr. Uli Hacksell, CEO of Medivir, will present t...

STOCKHOLM , May 13, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  today announces that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been presented at the 2019 Society for Investigati...

STOCKHOLM , May 7, 2019 /PRNewswire/ --  Medivir AB (Nasdaq Stockholm: MVIR) today announces that data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma patients, will be presented during the 2019 Society for Investigative Derm...

STOCKHOLM , May 6, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, has been presented as a poster during the Osteoarthritis Research Society International (OARSI) world congress. The poster title was Safety and E...

Medivir AB ( OTC:MVRBF ): Q1 GAAP EPS of -SEK2.30. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...